Clinical Study

Ea2165-A Randomized Phase II Study Of Nivolumab After Combined Modality Therapy (Cmt) In High Risk Anal Cancer

Posted Date: May 15, 2019

  • Investigator: Tahir Latif
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The goal of this study is to evaluate whether therapy with nivolumab following combined modality therapy (CMT) improves Disease-Free Survival (DFS) compared with observation in patients with high risk anal carcinoma/

Criteria:

To Be Eligible: Patient Must 18 Years Of Age Or Older, Patient Must Be Diagnosed With Stage Iib,Iiia, Iiib, Or Iiic Squamous Cell Carcinoma Of The Anus, Must Be Nonpregnant And Nonbreastfeeding, No Organ Transplant History, No Current Uncontrolled Infection Or Illness,

Keywords:

Anal Cancer, Phase Ii

For More Information:

Uc Cancer Institute
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.